Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Published in 2023 by
Funda Meric-Bernstam,
Nizar M. Tannir,
Othon Iliopoulos,
Richard J. Lee,
Melinda L. Telli,
Alice C. Fan,
Angela DeMichele 
,
Naomi B. Haas,
Manish R. Patel,
James J. Harding,
Martin H. Voss,
Taofeek K. Owonikoko,
Bradley Carthon,
Ramaprasad Srinivasan,
Johanna C. Bendell
and other authors.
,
Naomi B. Haas,
Manish R. Patel,
James J. Harding,
Martin H. Voss,
Taofeek K. Owonikoko,
Bradley Carthon,
Ramaprasad Srinivasan,
Johanna C. Bendell
and other authors.
